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Abstract
Aims: Systematic annual screening to detect sight- threatening diabetic retinopathy 
(STDR) is established in the United Kingdom. We designed an observational cohort 
study to provide up- to- date data for policy makers and clinical researchers on inci-
dence of key screening endpoints in people with diabetes attending one screening 
programme running for over 30 years.
Methods: All people with diabetes aged ≥12 years registered with general practices 
in the Liverpool health district were offered inclusion. Data sources comprised: pri-
mary care (demographics, systemic risk factors), Liverpool Diabetes Eye Screening 
Programme (retinopathy grading), Hospital Eye Services (slit lamp biomicroscopy 
assessment of screen positives).
Results: 133,366 screening episodes occurred in 28,384 people over 11 years. Overall 
incidences were: screen positive 6.7% (95% CI 6.5– 6.8), screen positive for retinopathy 
3.1% (3.0– 3.1), unassessable images 2.6% (2.5– 2.7), other significant eye diseases 1.0% 
(1.0– 1.1). 1.6% (1.6– 1.7) had sight- threatening retinopathy confirmed by slit lamp bi-
omicroscopy. The annual incidence of screen positive and screen positive for retinopathy 
showed consistent declines from 8.8%– 10.6% and 4.4%– 4.6% in 2007/09 to 4.4%– 6.8% 
and 2.3%– 2.9% in 2013/17, respectively. Rates of STDR (true positive) were consist-
ently below 2% after 2008/09. Screen positive rates were higher in first time attenders 
(9.9% [9.4– 10.2] vs. 6.1% [6.0– 6.2]) in part due to ungradeable images (4.1% vs. 2.3%) 
and other eye disease (2.4% vs. 0.8%). 4.5% (3.9– 5.2) of previous non- attenders had 
sight- threatening retinopathy. Compared with people with type 2 diabetes, those with 
type 1 disease demonstrated higher rates of screen positive (11.9% vs. 6.0%) and STDR 
(6.4% vs. 1.2%). Overall prevalence of any retinopathy was 27.2% (27.0– 27.4).
Conclusions: In an established screening programme with a stable population screen, 
positive rates show a consistent fall over time to a low level. Of those who are screen 
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1 |  INTRODUCTION
By 2045, an estimated 693 million people (9.9% of the global 
adult population) will have diabetes1 with around 10% hav-
ing sight- threatening diabetic retinopathy (STDR, DR).2 
Early detection and treatment of STDR is key to avoiding 
visual impairment in people living with diabetes (PWD).3- 6 
Laser photocoagulation remains the mainstay of treatment 
for proliferative disease, while intravitreal therapies are indi-
cated in most patients requiring treatment for maculopathy. 
Systematic annual screening to detect STDR is established 
in several countries including the United Kingdom and has 
greatly improved the detection of treatable disease.
Landmark epidemiological studies on DR are around 
30  years old,7,8 and while providing important underpin-
ning, data on incidence and progression are not directly ap-
plicable to screening programmes. As programmes become 
established, people with longstanding disease are detected 
reducing the prevlance in DR in the screening population. 
Data from screening programmes are limited and reporting 
is variable.9- 11 Screening populations are stable and provide 
large cohorts for longitudinal epidemiological studies and 
for interventional clinical studies of early disease, but their 
characteristics are changing as systematic screening becomes 
established and evolves. True positive cases are retained 
under hospital eye services (HES). Disease management has 
changed including improved glucose and blood pressure (BP) 
control, less smoking and longer life expectancy.
We conducted an observational cohort study of people 
attending during an 11- year period for DR screening in one 
established urban programme in England. Our study was 
conducted within the Individualised Screening for Diabetic 
Retinopathy (ISDR) programme of applied research in DR 
screening12,13 (www.isdrp roject.co.uk). Here, we present data 
on incidence of all key stages in the screening pathway, screen 
positive, screen positive due to DR and STDR. We aimed to 
provide up- to- date data to inform screening programmes, 
policy makers and clinical services and to support future 
clinical research in early retinopathy. We also investigated ret-
rospective data collected since the beginning of screening in 
Liverpool to gain additional insights into long- term changes 
in incidence.
interpretation, or writing of the report. 
The corresponding author had full access 
to all data in the study and has final 
responsibility for the decision to submit.
positive, fewer than 50% are screen positive for diabetic retinopathy. Most are due to 
sight threatening maculopathy. The annual incidence of STDR is under 2% suggest-
ing future work on redefining screen positive and supporting extended intervals for 
people at low risk. Higher rates of screen positive and STDR are seen in first time at-
tenders. Those who have never attended for screening should be specifically targeted.
K E Y W O R D S
incidence, prevalence, screen positive, screening, sight- threatening diabetic retinopathy
Novelty statement
• In an established urban diabetic retinopathy (DR) 
screening programme in England, screen positive 
rates show a consistent fall over time to a low level.
• The annual incidence of sight- threatening diabetic 
retinopathy (STDR) is low at under 2%. New pro-
liferative disease is rare. The majority of referrals 
from screening programmes are not due to DR.
• Higher rates of screen positive and STDR occur in first 
time attenders, in particular previous non- attenders, 
and in type 1 disease who should be targeted.
• Once a steady state has been reached, screening pro-
grammes should consider revising referral thresh-
olds and extending intervals for low- risk individuals.
Precis
• What is already known about this topic? Prevalence 
of diabetes is increasing worldwide against a back-
ground of inadequate and overstretched resources. 
Screening detects DR at a stage at which vision loss 
can be prevented; it is effective and cost- effective in 
high- income settings. Current programmes are de-
signed to address incidence and prevalence based on 
30- year- old data
• What is the key question? What is the incidence 
of DR, types of STDR and a screen positive result 
in an established screening programme? Can high 
risk groups be identified?
• What are the new findings? In an urban DR screen-
ing programme established for 30 years with a stable 
population, rates of screen positive and screen positive 
due to DR show a consistent fall over time to a low 
level. We report a consistently low annual incidence 
of STDR at under 2%. New proliferative disease is 
rare. Most referrals to the hospital eye service are for 
non- DR- related findings. Higher rates of screen posi-
tive and STDR are seen in first time attenders; previ-
ous non- attenders are at particular risk. Reporting of 
outcomes in the literature is highly variable.
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2 |  MATERIALS AND METHODS
2.1 | Setting: Liverpool Diabetes Eye 
Screening Programme
The Liverpool Diabetes Eye Screening Programme (LDESP) 
was established in 1991, reaching full coverage by 2003 
around the time of the introduction of the English National 
Diabetic Eye Screening Programme (NDESP). LDESP is one 
of 61 providers in the NDESP. The data domains held within 
the LDESP are shown in Figure 1 and apply to all English 
screening programmes. All PWD aged ≥12 years registered 
with a Liverpool general practice (GP; primary care) are con-
sidered eligible for routine screening apart from the following 
categories: moved out of area; seen by another programme; 
blind (no perception of light in both eyes). Of those individu-
als who are eligible, two groups are excluded: opted out of 
screening; medically unfit. Individuals are suspended from 
routine screening if they are attending the HES for any of 
the following: management of active diabetic eye disease; slit 
lamp biomicroscopy (SLB) due to ungradeable photographs; 
digital surveillance (monitoring of DR more frequently than 
annually by retinal photography in a dedicated surveillance 
clinic). The remaining people undergo active screening in the 
community by a qualified retinal screener at one of six pri-
mary care facilities across the city.
Screening in the NDESP involves technician- based dig-
ital photography through dilated pupils with at least two 
45° colour photographs and manual grading using the grad-
ing schema shown in Table S1. Screen positive is defined 
as moderate pre- proliferative retinopathy (R2 in the NDESP 
scheme) and above; and/or maculopathy (grade M1); and/
or other significant eye disease; or ungradeable images.14 
Screen positive individuals undergo clinical examination 
by an ophthalmologist trained in medical retina in dedi-
cated HES- based clinics. For the purposes of our analysis, 
this examination defines ‘true positive’ for STDR defined 
as follows: moderate/severe pre- proliferative DR or prolif-
erative DR (sight threatening retinopathy, STR) and/or sight 
threatening maculopathy (STM), i.e., any of the following 
features: multiple blot haemorrhages, venous beading, intra-
retinal microvascular abnormalities, new vessels, preretinal/
vitreous haemorrhage, fibrovascular proliferation, exudates 
within 1 disc diameter (1500 μm) of the foveal centre, group 
of exudates within the macula more than 0.5 disc area in size, 
retinal thickening within 1 disc diameter of the foveal centre, 
haemorrhages/microaneurysms with reduced vision.
2.2 | ISDR cohort study participants
All PWD registered with the LDESP covering a single urban 
health district in the north west of England were offered 
F I G U R E  1  Diabetic eye screening 
cohort management in England and Wales. 
Source: https://www.gov.uk/gover nment/ 
publi catio ns/diabe tic- eye- scree ning- cohor 
t- manag ement - overv iew/diabe tic- eye- scree 
ning- cohor t- manag ement Accessed 27 
January 2020
• How might this impact on clinical practice in the 
foreseeable future? Low rates of STDR suggest 
that the purpose of screening should be reassessed 
once a steady state has been reached with changes 
in the referral threshold and extended intervals 
for people at low risk. People newly added to a 
programme, in particular those with a history of 
previous non- attendance, should be specifically 
targeted.
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inclusion in the ISDR programme. The patient cohort was 
established in a recruitment process approved by the Preston 
North West NHS Ethics Committee (13/NW/0196) and the 
Royal Liverpool and Broadgreen University Hospitals NHS 
Trust (RLBUHT) governance teams. GPs in Liverpool were 
invited to participate commencing in June 2013 and continued 
until 2016 when all had agreed to participate. Recruitment oc-
curred for all PWD in each practice. Newly diagnosed PWD 
and those PWD moving into area were added via the LDESP 
throughout the study. Consent was through an ‘opt- out’. An 
invitation letter, information booklet and an opt- out form 
were sent to eligible participants. The dataset comprised data 
acquired both prospectively from June 2013 to September 
2017 and retrospectively for PWD who did not opt out from 
April 2006 to 2013. This latter data exhibited a censoring 
effect: governance rules removed data from PWD who had 
died prior to a practice joining the study and who therefore 
had no opportunity to opt out.
2.3 | Data sources and analysis
Data on PWD in the UK NHS are collected in primary care, 
within screening programmes and in secondary care. A purpose- 
built real- time dynamic data warehouse was developed to store 
data from these three previously unlinked sources: (i) primary 
care electronic records (demographic and systemic variables; 
EMIS Web, EMIS Health, Leeds, UK), (ii) LDESP (DR pho-
tographic grading from both eyes; ‘Orion’ database (Digital 
HealthCare, Cambridge UK) before 2013 and ‘OptoMize’ da-
tabase (Digital Health Care, then EMIS Health) from 2013), 
(iii) HES (SLB retinopathy grading at screen- positive as-
sessment clinics at the RLBUHT; ‘Diabolos’ [a bespoke MS 
Access database] before 2016 and ‘Patient Electronic Notes 
System’ [a bespoke graphical user interface application] from 
2016). Source data were validated against standard ranges.
This analysis incudes only individuals attending for DR 
screening in the community and their first follow- up in the 
HES. Collection of data on people attending the HES for man-
agement of active diabetic eye disease, SLB screening due to 
ungradeable photographs or hospital- based digital surveillance 
of DR was not possible; therefore, we are unable to report 
whole population data. For the purpose of analysis, the values 
of the time- dependent clinical variables closest to the time of 
the screen episodes (i.e., annual screening episodes) within a 
time window of 1 year prior to 1 week after the screening epi-
sode were used. For positive screen events, data from the first 
SLB recorded within 1 year of the positive screen event were 
used to provide the final outcome for that event. The first re-
corded screening attendance was defined as the first recorded 
screening attendance where there were no earlier recorded 
screening attendances or SLB records for that individual. Any 
other recorded attended screening appointment was defined as 
any screening appointment where there had been at least one 
earlier attended screening appointment or SLB.
Two thousand two hundred sixty- five participants from the 
cohort study were recruited to an RCT within the ISDR pro-
gramme and allocated to individualised interval screening.12 
For those allocated to 24- month intervals (who under normal 
circumstances would have been screened annually) data on an-
nual incidence were adjusted (with an assumed attendance pro-
portion of 0.85): 2015/16 226 individuals (266 * 0.85), 2016/17 
1232 individuals (1449*0.85). Of these, 2.7% were assumed 
to have type 1 diabetes and 89.9% type 2 diabetes. All were 
assumed to be screen negative at the first appointment (which 
under normal circumstances would have occurred 12 months 
before the allocated appointment at 24 months). Additionally, 
96.2% were assumed to be R0R0 and 3.8% to be R1R0.
3 |  RESULTS
3.1 | Dataset
The analysis dataset was extracted from the ISDR data ware-
house on 25 September 2017. The size of the dataset varied 
throughout the 11 years studied with year- end effects and vari-
ation due to sampling time. Figure 2 shows the distribution of 
data in the ISDR cohort study. Of 30,771 invited to participate 
up to this time point, 2191 (7.1%) opted out and 196 had no 
LDES or HES data leaving data on 28,384 PWD available for 
analysis. Table S2 shows the numbers of people on the LDESP 
register categorised by inclusion in the ISDR study and attend-
ance at 1 or more screening appointments in a screening year.
3.2 | Censoring effect
The number of individuals with at least one screening ap-
pointment recorded in our dataset increased each year be-
tween 2006/07 and 2014/15. Between 2006/07 and 2016/17, 
the median age increased from 60.3 to 64.5 years and the me-
dian disease duration from 2.3 to 7.0 years. In order to assess 
whether censoring altered our estimates of retinopathy, we 
examined rates of STDR during the time period with the most 
complete data: 2013/14 to 2016/2017. Of 28,580 individuals 
in the ISDR cohort, 2538 (8.9%) died. Rates of STDR were 
calculated from the last attended appointment. In individuals 
in whom STDR status was not missing, there was no sig-
nificant difference in STDR rates between subjects who died 
and those who did not: 164/2311 (7.1%; 95% CI 6.1– 8.2) vs. 
1571/23,331 (6.7%; 6.3– 7.0). We also performed exploratory 
modelling to investigate the effect of death in subjects pre- 
2013 (data not shown). Together, our analyses indicate that 
death appears to have had little or no confounding effect on 
estimated rates of STDR prior to 2013/2016.
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3.3 | Demographics
Overall demographics of the 11- year cohort are shown in 
Table 1. Gender proportions were relatively stable across all 
screening years (55%– 58% male, 40%– 43% female, 1%– 3% 
unknown). The proportion of individuals with type 1 diabetes 
decreased over time from 6.7% to 4.7%, while the proportion 
with type 2 diabetes increased from 76.1% to 81.6%. The pro-
portion with unknown diabetes type decreased proportionally 
from 17.2% to 13.7%. The median HbA1c was stable across 
all years (median: 50– 52  mmol/mol; 6.7%– 6.9%) although 
there was a high proportion of missing data prior to 2012/13.
3.4 | Incidence
Annual incidences of screen positive, STDR, STR and STM 
are shown in Table  2; 28,384 PWD attended at least one 
screening episode over the 11  years (total 133,366 screen-
ing episodes included). 6.7% (8906/133,366) were screen 
positive, 3.1% (4073/133366; 45.7% of screen positives) 
were screen positive for DR, 2.6% (3444/133,366; 38.7% 
of screen positives) due to ungradeable images and 1.0% 
(1389/133,366; 15.6% of screen positives) due to other sig-
nificant eye disease. The proportion of subjects with no DR 
recorded (prevalence) was 72.8% (96,437/132,544 [excludes 
822 unknown]) and with any DR in one or both eyes was 
27.2% (36,107/132,544). Within the screen negative epi-
sodes retinopathy was identified in one eye only in 15.4% 
(19,726/128,471) and in both eyes in 9.6% (12,308/128,471).
In 7803 screen positive episodes, individuals attended the 
HES and were examined by a medical retina specialist. 28.2% 
(2193/7777 with known STDR status) had STDR (true pos-
itive) of whom 35.8% (781/2179 with known STR/STM sta-
tus) had STR and 82.7% (1802/2179) had STM. STDR was 
detected in 1.6% (2193/133,366) of all screen episodes, STR 
in 0.6% (781/133,366) and STM in 1.4% (1802/133,366). 
Of the people referred as screen positive for DR, 53.8% 
(2193/4073) had STDR. The proportion of subjects who were 
screen positive but did not have a recorded SLB in the data-
set was 0.8% (1103/133,366). Reasons for this include legiti-
mate events (failure to attend two consecutive appointments; 
F I G U R E  2  Data flows in the Individualised Screening for Diabetic Retinopathy cohort study with numbers from an illustrative time point of 
25 September 2017
Number of people invited to participate in the ISDR cohort study from
21st June 2013 to 25th September 2017 n = 30,771
Numberof people opted out of the ISDR
cohort study n = 2,191
Numberof participants with data in the ISDR Data Warehouse
n = 28,580
Participants with at least one recorded covariate in EMIS between
26th February 2009 and 20th September 2017 n = 26,819
Participants with at least one screening episode between
5th December 2005 and 29th August 2017 n= 25,864
Participants with at least onebiomicroscopydata between
19thJuly 1991 and 17th November 2017 n= 9,186
1st April 2006–31st March 2017 Cohort dataset
n= 28,384
Numberof people with no LDES or HES data
n= 196
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death; moved out of area) as well as missing data which could 
not be recovered.
There was some variation across the years of rates of 
screen positive with an overall reduction over the 11 years 
from 8.8%– 10.6% in 2007/09 to 4.4%– 6.8% in 2013/17. 
The annual incidence of screen positive due to DR also de-
creased over the 11  years from 4.4%– 4.6% in 2007/09 to 
2.3%– 2.9% in 2013/17. In contrast rates of screen positive 
for ungradeable images were stable, fluctuating around 2%– 
3%, similarly other eye disease was stable at around 1%. 
Rates of STDR (true positive; examined by a medical retina 
specialist using SLB) were relatively stable between 1.3% 
and 2.2%. STR at 0.4%– 0.9% and STM at 1.1%– 1.8% were 
also stable. Figure 3 illustrates these trends over time. Out 
of those with a known retinopathy level, the proportion of 
subjects with no DR rose steadily from 61.8% in 2006/07 to 
79.4% in 2016/17.
3.5 | First time attenders
Tables 3 and 4 show the annual incidences of screen posi-
tive, STDR, STR and STM for individuals attending their 
first recorded screening appointment and for those attending 
a screening appointment which was not their first recorded 
screening episode, respectively. Data are displayed from 
screening year 2007/08 to allow for at least a full year of data 
collection prior to a first recorded screening event. Compared 
to people already attending screening, rates in first time at-
tenders for screen positive were ×1.6 higher (9.9% vs. 6.1%) 
and for STDR ×1.4 higher (2.2 vs. 1.6). Much of this screen 
positive effect appears to be due to unassessable images 
(×1.8, 4.1% vs. 2.3%) and other eye disease (×3.0, 2.4% vs. 
0.8%). Figures S1 and S2 show a graphical representation of 
the annual incidences of screen positive, screen positive for 
DR, STDR and STR in these two groups.
People living with diabetes attending for DR screening for 
the first time are a heterogeneous group comprising people 
newly diagnosed with diabetes and those with existing dia-
betes who were previous non- attenders. We investigated the 
annual incidences of screen positive, STDR, STR and STM 
for individuals attending their first recorded screening ap-
pointment where disease duration was ≤1 year (i.e., newly di-
agnosed) and where disease duration was greater than 1 year 
(Tables S3 and S4). The overall screen positive rate across all 
study years in the newly diagnosed group and those with dia-
betes >1 year was 8.4% (8.0– 8.9, 95% CI) and 14.3% (13.2– 
15.4), respectively. Both figures are higher than the rate in 
people who had already attended at least one screening ap-
pointment: 6.1% (6.0– 6.2). Similar but stronger effects were 
seen for rates of screen positive for DR (newly diagnosed di-
abetes 2.2% [2.0– 2.5]; diabetes duration >1  year attending 
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previous screening event 2.9% [2.8– 3.0]) and true positive 
STDR (1.4% [1.2– 1.6], 4.5% [3.9– 5.2], 1.6% [1.5– 1.6]).
3.6 | Type 1 and type 2 diabetes
Tables S5 and S6 show the annual incidences by diabetes 
type of screen positive, STDR, STR and STM for individuals 
with known type of diabetes. Rates of both screen positive 
(11.9% vs. 6.0%) and screen positive due to DR (10.7% vs. 
2.3%) were higher in people with type 1 diabetes. Rates of 
STDR were much higher (6.4% vs. 1.2%) in type 1 diabetes; a 
higher proportion of STDR was due to STR (47% vs. 33%) in 
these individuals. Both unassessable images (0.8% vs. 2.7%) 
and other eye disease (0.4% vs. 1.1%) were lower in type 1 
diabetes. Across the 11 years of the study, there was a fall 
in screen positive, screen positive for DR and STDR in both 
type 1 and type 2 diabetes consistent with overall rates.
4 |  DISCUSSION
In this observational cohort study of people with diabetes at-
tending an established retinopathy screening programme, we 
T A B L E  2  Annual incidences of screen positive, sight- threatening diabetic retinopathy (STDR), sight threatening retinopathy (STR) and sight  
threatening maculopathy (STM) for people with diabetes who attended at least one screening episode in each screening year (1 April– 31 March)  
between 2006 and 2017
Screening year
Overall
n [%; 95% CI]2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17
Individuals who attended at least one screening 
appointment (n [%])
6637 [100.0] 8088 [100.0] 8664 [100.0] 10,266 [100.0] 11,214 [100.0] 13,124 [100.0] 13,518 [100.0] 15,115 [100.0] 15,518 [100.0] 15,221b [100.0] 16,001b [100.0] 133,366 [100.0]
Overall screen positive 527 [7.9] 714 [8.8] 922 [10.6] 854 [8.3] 695 [6.2] 921 [7.0] 774 [5.7] 669 [4.4] 805 [5.2] 1031 [6.8] 994 [6.2] 8906 [6.7; 6.5– 6.8]
Screen positive for DR 271 [4.1] 355 [4.4] 401 [4.6] 360 [3.5] 327 [2.9] 419 [3.2] 330 [2.4] 345 [2.3] 387 [2.5] 441 [2.9] 437 [2.7] 4073 [3.1; 3.0– 3.1]
Screen positive for unassessable images 201 [3.0] 255 [3.2] 358 [4.1] 372 [3.6] 283 [2.5] 425 [3.2] 322 [2.4] 179 [1.2] 258 [1.7] 408 [2.7] 383 [2.4] 3444 [2.6; 2.5– 2.7]
Screen positive for other eye disease 55 [0.8] 104 [1.3] 163 [1.9] 122 [1.2] 85 [0.8] 77 [0.6] 122 [0.9] 145 [1.0] 160 [1.0] 182 [1.2] 174 [1.1] 1389 [1.0; 1.0– 1.1]
Biomicroscopy recordeda 446 [6.7] 618 [7.6] 794 [9.2] 712 [6.9] 612 [5.5] 774 [5.9] 650 [4.8] 621 [4.1] 742 [4.8] 965 [6.3] 869 [5.4] 7803 [5.9; 5.7– 6.0]
STDR 116 [1.7] 145 [1.8] 192 [2.2] 178 [1.7] 160 [1.4] 223 [1.7] 179 [1.3] 212 [1.4] 246 [1.6] 251 [1.6] 291 [1.8] 2193 [1.6; 1.6– 1.7]
STR 41 [0.6] 44 [0.5] 81 [0.9] 65 [0.6] 56 [0.5] 75 [0.6] 57 [0.4] 69 [0.5] 98 [0.6] 85 [0.6] 110 [0.7] 781 [0.6; 0.5– 0.6]
STM 91 [1.4] 119 [1.5] 157 [1.8] 135 [1.3] 130 [1.2] 197 [1.5] 149 [1.1] 79 [1.2] 191 [1.2] 216 [1.4] 238 [1.5] 1802 [1.4; 1.3– 1.4]
STR & STM unknown 0 [0.0] 0 [0.0] 2 [<0.1] 2 [<0.1] 4 [<0.1] 0 [0.0] 4 [<0.1] 1 [<0.1] 1 [<0.1] 0 [0.0] 0 [0.0] 14 [<0.1; 0.0– 0.0]
Not STDR 330 [5.0] 473 [5.8] 602 [6.9] 534 [5.2] 452 [4.0] 551 [4.2] 471 [3.5] 406 [2.7] 496 [3.2] 714 [4.7] 555 [3.5] 5584 [4.2; 4.1– 4.3]
Unknown STDR status 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 3 [<0.1] 0 [0.0] 0 [0.0] 23 [0.1] 26 [<0.1; 0.0– 0.0]
No biomicroscopy recordeda 81 [1.2] 96 [1.2] 128 [1.5] 142 [1.4] 83 [0.7] 147 [1.1] 124 [0.9] 48 [0.3] 63 [0.4] 66 [0.4] 125 [0.8] 1103 [0.8; 0.8– 0.9]
Screen negative 6110 [92.1] 7374 [91.2] 7742 [89.4] 9412 [91.7] 10519 [93.8] 12203 [93.0] 12744 [94.3] 14446 [95.6] 14713 [94.8] 14190 [93.2] 15007 [93.8] 124460 [93.3; 93.2– 93.5]
Retinopathy level
Screen negative DR
R0R0 3978 [59.9] 4901 [60.6] 5440 [62.8] 6536 [63.7] 7805 [69.6] 9093 [69.3] 9547 [70.6] 11,030 [73.0] 11,658 [75.1] 11,506 [75.6]b 12,407 [77.5]b 93901 [70.4; 70.2– 70.7]
R1R0 1205 [18.2] 1536 [19.0] 1545 [17.8] 1906 [18.6] 1646 [14.7] 1938 [14.8] 2032 [15.0] 1971 [13.0] 1845 [11.9] 1799 [11.8]b 1631 [10.2]b 19,054 [14.3; 14.1– 14.5]
R1R1 947 [14.3] 994 [12.3] 879 [10.1] 1065 [10.4] 1124 [10.0] 1205 [9.2] 1239 [9.2] 1509 [10.0] 1289 [8.3] 993 [6.5] 1064 [6.6] 12,308 [9.2; 9.1– 9.4]
One assessable eye (R0) 166 [2.5] 168 [2.1] 186 [2.1] 167 [1.6] 143 [1.3] 228 [1.7] 210 [1.6] 211 [1.4] 277 [1.8] 392 [2.6] 388 [2.4] 2536 [1.9; 1.8– 2.0]
One assessable eye (R1) 54 [0.8] 52 [0.6] 57 [0.7] 64 [0.6] 64 [0.6] 65 [0.5] 61 [0.5] 47 [0.3] 57 [0.4] 85 [0.6] 66 [0.4] 672 [0.5; 0.5– 0.5]
Unknown 6 [0.2] 82 [1.0] 156 [1.8] 168 [1.6] 105 [0.9] 176 [1.3] 99 [0.7] 2 [<0.1] 5 [<0.1] 5 [<0.1] 8 [<0.1] 822 [0.6; 0.6– 0.7]
Screen positive DR
R2 or M1 256 [3.9] 344 [4.3] 375 [4.3] 339 [3.3] 309 [2.8] 398 [3.0] 314 [2.3] 331 [2.2] 387 [2.5] 441 [2.9] 437 [2.7] 3931 [2.9; 2.9– 3.0]
R3 15 [0.2] 11 [0.1] 26 [0.3] 21 [0.2] 18 [0.2] 21 [0.2] 16 [0.1] 14 [0.1] 0 [0.0] 0 [0.0] 0 [0.0] 142 [0.1; 0.1– 0.1]
Note: Denominator for a given year is the total number of individuals who attended at least one screening appointment during that year. For example, for screening  
year 2012– 13, the denominator is 13,518, and the annual incidence of overall screen positive is 5.7% (774/13,518). STM and STR are not mutually exclusive categories.  
95% CI are based on the Wilson score method.
Abbreviation: DR, diabetic retinopathy.
aBiomicroscopy recorded within 1 year of screening appointment when positive screen result occurred.
bAdjusted for subjects recruited to the ISDR RCT and assigned to 24- month screening intervals.
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report estimates of incidence of key stages in the diabetes eye 
care pathway. Average annual incidences across the 11 years 
studied were 6.7% for screen positive, 3.1% screen positive 
due to DR, 1.0% other significant eye disease and 2.6% un-
gradeable images. 1.6% had STDR confirmed by a medical 
retina specialist. The prevalence of any DR was 27.2%. Our 
latest estimates of the incidence of STDR should be seen 
in the context of STDR rates recorded since 1991/92 in the 
LDESP. From an initial 6.9%, a steady fall was observed dur-
ing the phased roll- out of screening over 16 years to 1.8% 
in 2007/08 (screening programme data; available on request 
from authors). These long- term observed data are likely to 
represent a ‘first pass effect’ where existing disease is de-
tected in a population screened for the first time.
Other factors may have influenced the observed decline 
in STDR rates from the early years of screening in Liverpool. 
Medical care for PWD has improved over this time. Diagnostic 
criteria for diabetes have changed in recent years,15 and there 
have been concerted efforts to detect diabetes early. A sim-
ilar reduction in more advanced stages of disease was iden-
tified in a systematic literature review by Liew et al.,16 who 
reported a two to threefold reduction in PDR and DMO over 
the last 30 years. Over the 11 years, there was a gradual fall 
in the prevalence of DR in the screened population from 38% 
T A B L E  2  Annual incidences of screen positive, sight- threatening diabetic retinopathy (STDR), sight threatening retinopathy (STR) and sight  
threatening maculopathy (STM) for people with diabetes who attended at least one screening episode in each screening year (1 April– 31 March)  
between 2006 and 2017
Screening year
Overall
n [%; 95% CI]2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17
Individuals who attended at least one screening 
appointment (n [%])
6637 [100.0] 8088 [100.0] 8664 [100.0] 10,266 [100.0] 11,214 [100.0] 13,124 [100.0] 13,518 [100.0] 15,115 [100.0] 15,518 [100.0] 15,221b [100.0] 16,001b [100.0] 133,366 [100.0]
Overall screen positive 527 [7.9] 714 [8.8] 922 [10.6] 854 [8.3] 695 [6.2] 921 [7.0] 774 [5.7] 669 [4.4] 805 [5.2] 1031 [6.8] 994 [6.2] 8906 [6.7; 6.5– 6.8]
Screen positive for DR 271 [4.1] 355 [4.4] 401 [4.6] 360 [3.5] 327 [2.9] 419 [3.2] 330 [2.4] 345 [2.3] 387 [2.5] 441 [2.9] 437 [2.7] 4073 [3.1; 3.0– 3.1]
Screen positive for unassessable images 201 [3.0] 255 [3.2] 358 [4.1] 372 [3.6] 283 [2.5] 425 [3.2] 322 [2.4] 179 [1.2] 258 [1.7] 408 [2.7] 383 [2.4] 3444 [2.6; 2.5– 2.7]
Screen positive for other eye disease 55 [0.8] 104 [1.3] 163 [1.9] 122 [1.2] 85 [0.8] 77 [0.6] 122 [0.9] 145 [1.0] 160 [1.0] 182 [1.2] 174 [1.1] 1389 [1.0; 1.0– 1.1]
Biomicroscopy recordeda 446 [6.7] 618 [7.6] 794 [9.2] 712 [6.9] 612 [5.5] 774 [5.9] 650 [4.8] 621 [4.1] 742 [4.8] 965 [6.3] 869 [5.4] 7803 [5.9; 5.7– 6.0]
STDR 116 [1.7] 145 [1.8] 192 [2.2] 178 [1.7] 160 [1.4] 223 [1.7] 179 [1.3] 212 [1.4] 246 [1.6] 251 [1.6] 291 [1.8] 2193 [1.6; 1.6– 1.7]
STR 41 [0.6] 44 [0.5] 81 [0.9] 65 [0.6] 56 [0.5] 75 [0.6] 57 [0.4] 69 [0.5] 98 [0.6] 85 [0.6] 110 [0.7] 781 [0.6; 0.5– 0.6]
STM 91 [1.4] 119 [1.5] 157 [1.8] 135 [1.3] 130 [1.2] 197 [1.5] 149 [1.1] 79 [1.2] 191 [1.2] 216 [1.4] 238 [1.5] 1802 [1.4; 1.3– 1.4]
STR & STM unknown 0 [0.0] 0 [0.0] 2 [<0.1] 2 [<0.1] 4 [<0.1] 0 [0.0] 4 [<0.1] 1 [<0.1] 1 [<0.1] 0 [0.0] 0 [0.0] 14 [<0.1; 0.0– 0.0]
Not STDR 330 [5.0] 473 [5.8] 602 [6.9] 534 [5.2] 452 [4.0] 551 [4.2] 471 [3.5] 406 [2.7] 496 [3.2] 714 [4.7] 555 [3.5] 5584 [4.2; 4.1– 4.3]
Unknown STDR status 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 3 [<0.1] 0 [0.0] 0 [0.0] 23 [0.1] 26 [<0.1; 0.0– 0.0]
No biomicroscopy recordeda 81 [1.2] 96 [1.2] 128 [1.5] 142 [1.4] 83 [0.7] 147 [1.1] 124 [0.9] 48 [0.3] 63 [0.4] 66 [0.4] 125 [0.8] 1103 [0.8; 0.8– 0.9]
Screen negative 6110 [92.1] 7374 [91.2] 7742 [89.4] 9412 [91.7] 10519 [93.8] 12203 [93.0] 12744 [94.3] 14446 [95.6] 14713 [94.8] 14190 [93.2] 15007 [93.8] 124460 [93.3; 93.2– 93.5]
Retinopathy level
Screen negative DR
R0R0 3978 [59.9] 4901 [60.6] 5440 [62.8] 6536 [63.7] 7805 [69.6] 9093 [69.3] 9547 [70.6] 11,030 [73.0] 11,658 [75.1] 11,506 [75.6]b 12,407 [77.5]b 93901 [70.4; 70.2– 70.7]
R1R0 1205 [18.2] 1536 [19.0] 1545 [17.8] 1906 [18.6] 1646 [14.7] 1938 [14.8] 2032 [15.0] 1971 [13.0] 1845 [11.9] 1799 [11.8]b 1631 [10.2]b 19,054 [14.3; 14.1– 14.5]
R1R1 947 [14.3] 994 [12.3] 879 [10.1] 1065 [10.4] 1124 [10.0] 1205 [9.2] 1239 [9.2] 1509 [10.0] 1289 [8.3] 993 [6.5] 1064 [6.6] 12,308 [9.2; 9.1– 9.4]
One assessable eye (R0) 166 [2.5] 168 [2.1] 186 [2.1] 167 [1.6] 143 [1.3] 228 [1.7] 210 [1.6] 211 [1.4] 277 [1.8] 392 [2.6] 388 [2.4] 2536 [1.9; 1.8– 2.0]
One assessable eye (R1) 54 [0.8] 52 [0.6] 57 [0.7] 64 [0.6] 64 [0.6] 65 [0.5] 61 [0.5] 47 [0.3] 57 [0.4] 85 [0.6] 66 [0.4] 672 [0.5; 0.5– 0.5]
Unknown 6 [0.2] 82 [1.0] 156 [1.8] 168 [1.6] 105 [0.9] 176 [1.3] 99 [0.7] 2 [<0.1] 5 [<0.1] 5 [<0.1] 8 [<0.1] 822 [0.6; 0.6– 0.7]
Screen positive DR
R2 or M1 256 [3.9] 344 [4.3] 375 [4.3] 339 [3.3] 309 [2.8] 398 [3.0] 314 [2.3] 331 [2.2] 387 [2.5] 441 [2.9] 437 [2.7] 3931 [2.9; 2.9– 3.0]
R3 15 [0.2] 11 [0.1] 26 [0.3] 21 [0.2] 18 [0.2] 21 [0.2] 16 [0.1] 14 [0.1] 0 [0.0] 0 [0.0] 0 [0.0] 142 [0.1; 0.1– 0.1]
Note: Denominator for a given year is the total number of individuals who attended at least one screening appointment during that year. For example, for screening  
year 2012– 13, the denominator is 13,518, and the annual incidence of overall screen positive is 5.7% (774/13,518). STM and STR are not mutually exclusive categories.  
95% CI are based on the Wilson score method.
Abbreviation: DR, diabetic retinopathy.
aBiomicroscopy recorded within 1 year of screening appointment when positive screen result occurred.
bAdjusted for subjects recruited to the ISDR RCT and assigned to 24- month screening intervals.
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to 21% with equivalent falls in annual rates of screen positive 
and screen positive for DR. In contrast STDR, rates remained 
relatively stable at under 2.0%. This steady decline in diag-
nostic categories prior to the STDR stage requires further 
research. They may represent improvements in grading. A 
lowering of the threshold for the diagnosis of diabetes 15 may 
have increased the proportions with no retinopathy.
The strengths of our study include the size of the dataset 
and the duration of data collection.
HbA1c levels were generally well controlled in our popu-
lation. This may reflect current standards of medical care but 
better compliance with medical care amongst those attending 
screening cannot be excluded. The current prevalence of di-
abetes in adults aged 17+ in Liverpool is 6.6% (29,993 peo-
ple), slightly lower than the 7.1% in England as a whole.17 
DR screening coverage in Liverpool is low compared to other 
programmes: 80.4% in year April 2016 to March 2017.18 
The main limitation of our study is the mixed prospective 
and retrospective dataset reflecting changes in governance 
regulations and data collection platforms, a common issue 
in long- term, observational studies of real- world collected 
data. Around 5% of the population died or moved away each 
year and without consent, we were unable to access their his-
torical data. This censoring could have affected our findings 
between 2006/7 and 2012/13 and is seen in the change in 
median age and disease duration. Subjects with worse reti-
nopathy would be expected to have higher mortality, so our 
numerators may be underestimates. However, our exploratory 
analyses suggested that taking this effect into account would 
have a negligible effect on STDR rates. The ISDR RCT com-
menced in 2014 resulting in a proportion of patients moving 
to 2- yearly screening. We corrected for this effect in the last 
2 years of our analysis.
In this study, we report results from PWD attending 
screening. Collection of data on people attending the HES 
with other eye disease (who undergo screening in the HES) 
was not possible; therefore, we cannot report whole popula-
tion data. In Liverpool in 2017/18, 9.4% (2054/21,853) of 
PWD were attending the HES for management of DR or slit 
lamp- based screening. Nonetheless, it is possible to estimate 
a rate of STDR in people attending screening of 164/10,000 
PWD/annum (2193/133,366  *  10,000). Comparison of 
our data with other studies is limited by the inconsistent 
and incomplete reporting of different screening outcomes. 
Longitudinal cohort studies from our group,19,20 and from 
Norwich 21 and Wales,22 have estimated annual incidences of 
preproliferative retinopathy and maculopathy. Looker et al. 9  
reported data from the first 5 years of the DR Screening in 
Scotland. Rates of referable eye disease equivalent to our 
screen positive due to DR were highest in the first 2 years of 
screening (7.0% 2006, 6.0% 2007) before stabilising at 4.3%, 
slightly higher than our 3.1%.
Misra et al.10 reported data from 20,788 PWD undergo-
ing annual retinal photography between 1990 and 2006 in 
one English region. Rates of referable retinopathy (NDESP 
grades R2 or R3 or M1) increased from 2.0% in 1990 to 6.7% 
in 2001, then decreased to 4.7% by 2006. Scanlon et al.11 
reported a rate of referable retinopathy/STDR of 2.3% in a 
F I G U R E  3  Graphical illustration of the annual incidences of screen positive, screen positive for diabetic retinopathy (DR), sight- threatening 
diabetic retinopathy (STDR) and sight threatening retinopathy (STR) for people living with diabetes categorised by screening year (1 April– 31 
March) between 2006 and 2017. Solid lines represent proportions, and the corresponding 95% confidence intervals based on the Wilson score 
method are represented by dashed lines
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screening cohort from Gloucestershire used for a cost effec-
tiveness modelling study. None of these studies appear to 
have reported true positive STDR after confirmation by a 
medical retina specialist, considered as the clinical standard 
for treatment decision making. Authors should report screen 
positive due to DR, other eye disease and ungradeable images 
in addition to true STDR (confirmed by a medical retina spe-
cialist). Standardisation of outcomes reporting across regions 
and countries would aid comparison.
In our study, around half (53.8%) of subjects who were 
screen positive for DR had STDR. Of these people with true 
STDR, 82.7% had STM and 35.5% had STR. The proportion 
was similar when comparing new and previously acquired 
screened patients and similar to reports from Scotland in 
2010 where 73% of referrals for DR were due to maculop-
athy.9 We report very low rates of R3 with none in the last 
3 years. Compared to STR, STM is more expensive to treat 
and monitor. Our results are of interest to health service pro-
viders and to researchers developing new therapies who re-
quire candidates for clinical trials.
Current UK screening definitions and pathways were es-
tablished over 15  years ago to support the introduction of 
screening and were consensus based.23 Now that the rates of 
STDR are low, it may be appropriate to revisit the definition 
of screen positive in order to ensure optimum resource al-
location. Extended screening intervals should be considered 
by programme managers; data on the proportions of patients 
with R1/R0 and R1/R1 will inform risk stratification.13,24 The 
T A B L E  4  Annual incidences of screen positive, sight- threatening diabetic retinopathy (STDR), sight threatening retinopathy (STR) and sight  
threatening maculopathy (STM) for individuals attending a screening appointment in each screening year (1 April– 31 March) which was not their  
first recorded screening episode between 2007 and 2017
Screening year
Overall
n [%; 95% CI]2007/08 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17
Individuals attended screening appointment (excluding 
first recorded events) n [%]
6349 [100.0] 7155 [100.0] 8769 [100.0] 9585 [100.0] 11,248 [100.0] 12,037 [100.0] 13,561 [100.0] 13,904 [100.0] 13,597b [100.0] 14,135b [100.0] 11,0340 [100.0]
Overall screen positive 486 [7.7] 698 [9.8] 686 [7.8] 549 [5.7] 724 [6.4] 644 [5.4] 557 [4.1] 676 [4.9] 875 [6.4] 835 [5.9] 6730 [6.1; 6.0– 6.2]
Screen positive for DR 258 [4.1] 334 [4.7] 13 [3.6] 276 [2.9] 355 [3.2] 289 [2.4] 305 [2.2] 338 [2.4] 387 [2.8] 382 [2.7] 3237 [2.9; 2.8– 3.0]
Screen positive for unassessable images 173 [2.7] 271 [3.8] 285 [3.3] 212 [2.2] 322 [2.9] 265 [2.2] 146 [1.1] 215 [1.5] 353 [2.6] 321 [2.3] 2563 [2.3; 2.2– 2.4]
Screen positive for other eye disease 55 [0.9] 93 [1.3] 88 [1.0] 61 [0.6] 47 [0.4] 90 [0.7] 106 [0.8] 123 [0.9] 135 [1.0] 132 [0.9] 930 [0.8; 0.8– 0.9]
Biomicroscopy recordeda 432 [6.8] 598 [8.4] 578 [6.6] 485 [5.1] 605 [5.4] 537 [4.5] 515 [3.8] 623 [4.5] 820 [6.0] 725 [5.1] 5918 [5.4; 5.2– 5.5]
STDR 106 [1.7] 155 [2.2] 148 [1.7] 129 [1.3] 181 [1.6] 149 [1.2] 179 [1.3] 210 [1.5] 211 [1.6] 246 [1.7] 1714 [1.6; 1.5– 1.6]
STR 29 [0.5] 55 [0.8] 47 [0.5] 42 [0.4] 55 [0.5] 44 [0.4] 55 [0.4] 75 [0.5] 71 [0.5] 87 [0.6] 560 [0.5; 0.5– 0.6]
STM 84 [1.3] 128 [1.8] 115 [1.3] 105 [1.1] 158 [1.4] 123 [1.0] 151 [1.1] 168 [1.2] 181 [1.3] 200 [1.4] 1413 [1.3; 1.2– 1.3]
Unknown STR & Unknown STM 0 [0.0] 2 [<0.1] 1 [<0.1] 3 [<0.1] 0 [0.0] 4 [<0.1] 1 [<0.1] 1 [<0.1] 0 [0.0] 0 [0.0] 12 [<0.1; 0.0– 0.0]
Not STDR 326 [5.1] 443 [6.2] 430 [4.9] 356 [3.7] 424 [3.8] 388 [3.2] 333 [2.5] 413 [3.0] 609 [4.5] 459 [3.2] 4181 [3.8; 3.7– 3.9]
Unknown STDR status 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 3 [<0.1] 0 [0.0] 0 [0.0] 20 [0.1] 23 [<0.1; 0.0– 0.0]
No biomicroscopy recordeda 54 [0.9] 100 [1.4] 108 [1.2] 64 [0.7] 119 [1.1] 107 [0.9] 42 [0.3] 53 [0.4] 55 [0.4] 110 [0.8] 812 [0.7; 0.7– 0.8]
Screen negative 5863 [92.3] 6457 [90.2] 8083 [92.2] 9036 [94.3] 10524 [93.6] 11393 [94.6] 13004 [95.9] 13228 [95.1] 12722 [93.6] 13300 [94.1] 103,610 [93.9; 93.8– 94.0]
Retinopathy level
Screen negative DR
R0R0 3816 [60.1] 4390 [61.4] 5476 [62.4] 6570 [68.5] 7682 [68.3] 8432 [70.1] 791 [72.2] 10370 [74.6] 10166 [74.8]b 10850 [76.8]b 77,543 [70.3; 70.0– 70.5]
R1R0 1234 [19.4] 1327 [18.5] 1673 [19.1] 1475 [15.4] 1727 [15.4] 1838 [15.3] 1812 [13.4] 1694 [12.2] 1666 [12.3]b 1488 [10.5]b 15,934 [14.4; 14.2– 14.6]
R1R1 830 [13.1] 800 [11.2] 1000 [11.4] 1030 [10.7] 1124 [10.0] 1172 [9.7] 1433 [10.6] 1213 [8.7] 959 [7.1] 1022 [7.2] 10,583 [9.6; 9.4– 9.8]
One assessable eye (R0) 117 [1.8] 132 [1.8] 125 [1.4] 109 [1.1] 171 [1.5] 182 [1.5] 174 [1.3] 230 [1.7] 339 [2.5] 331 [2.3] 1910 [1.7; 1.7– 1.8]
One assessable eye (R1) 5 [0.6] 48 [0.7] 56 [0.6] 57 [0.6] 5 [0.5] 52 [0.4] 44 [0.3] 54 [0.4] 76 [0.6] 54 [0.4] 531 [0.5; 0.4– 0.5]
Unknown 59 [0.9] 124 [1.7] 126 [1.4] 68 [0.7] 134 [1.2] 72 [0.6] 2 [<0.1] 5 [<0.1] 4 [<0.1] 8 [0.1] 602 [0.5; 0.5– 0.6]
Screen positive DR
R2 or M1 253 [4.0] 317 [4.4] 301 [3.4] 262 [2.7] 344 [3.1] 279 [2.3] 292 [2.2] 338 [2.4] 387 [2.8] 382 [2.7] 3155 [2.9; 2.8– 3.0]
R3 5 [0.1] 17 [0.2] 12 [0.1] 14 [0.1] 11 [0.1] 10 [0.1] 13 [0.1] 0 [0.0] 0 [0.0] 0 [0.0] 82 [0.1; 0.1– 0.1]
Note: STM and STR are not mutually exclusive categories. 95% CI are based on the Wilson score method.
Abbreviation: DR, diabetic retinopathy.
aBiomicroscopy must be recorded within 1 year of screening appointment when positive screen result occurred.
bAdjusted for subjects recruited to the ISDR RCT and assigned to 24- month screening intervals.
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low rates also support moves to introduce personalised risk- 
based variable- interval screening using clinical risk factor 
data.12,25 Of those identified as screen positive in our study, 
only 28.1% had true positive disease. A high proportion of 
screen positive cases were due to ungradeable images (most 
likely due to cataract) and other significant eye disease, iden-
tification of which is not an objective of screening. New 
technologies may overcome ungradeable images (38.7% in 
our study); agreement is needed on approaches to managing 
screen positive due to other eye disease (15.7% in our study).
Despite high rates of ungradeable images, newly screened 
PWD in our study demonstrated rates of STDR 1.4× higher 
than existing screening participants (2.2% vs. 1.6%). This 
effect appears to be driven by previous non- attenders and 
is consistently seen in other epidemiological studies. In the 
United Kingdom Prospective Diabetes Study (type 2 disease), 
4.5% of female and 7.9% of male participants had STDR at 
diagnosis of diabetes,26 while the LDES reported 6.6% (9.8% 
for Type 1) having STDR at first screen.19,20 In the Scottish 
programme, 6.9% of first- time attenders had referable dis-
ease compared to 3% for people attending their fourth or fifth 
screen.9 New systematic DR screening programmes in Asia 
report similar findings. In Hong Kong, where screening fol-
lowing the English NDESP protocol was introduced for the 
first time in 2014, STDR was detected in 9.8% of 174,532 
new screened patients in 12 months.27 A phased introduction 
of screening into populations may reduce the service delivery 
pressures on HES. We report higher rates of screen positive 
T A B L E  4  Annual incidences of screen positive, sight- threatening diabetic retinopathy (STDR), sight threatening retinopathy (STR) and sight  
threatening maculopathy (STM) for individuals attending a screening appointment in each screening year (1 April– 31 March) which was not their  
first recorded screening episode between 2007 and 2017
Screening year
Overall
n [%; 95% CI]2007/08 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17
Individuals attended screening appointment (excluding 
first recorded events) n [%]
6349 [100.0] 7155 [100.0] 8769 [100.0] 9585 [100.0] 11,248 [100.0] 12,037 [100.0] 13,561 [100.0] 13,904 [100.0] 13,597b [100.0] 14,135b [100.0] 11,0340 [100.0]
Overall screen positive 486 [7.7] 698 [9.8] 686 [7.8] 549 [5.7] 724 [6.4] 644 [5.4] 557 [4.1] 676 [4.9] 875 [6.4] 835 [5.9] 6730 [6.1; 6.0– 6.2]
Screen positive for DR 258 [4.1] 334 [4.7] 13 [3.6] 276 [2.9] 355 [3.2] 289 [2.4] 305 [2.2] 338 [2.4] 387 [2.8] 382 [2.7] 3237 [2.9; 2.8– 3.0]
Screen positive for unassessable images 173 [2.7] 271 [3.8] 285 [3.3] 212 [2.2] 322 [2.9] 265 [2.2] 146 [1.1] 215 [1.5] 353 [2.6] 321 [2.3] 2563 [2.3; 2.2– 2.4]
Screen positive for other eye disease 55 [0.9] 93 [1.3] 88 [1.0] 61 [0.6] 47 [0.4] 90 [0.7] 106 [0.8] 123 [0.9] 135 [1.0] 132 [0.9] 930 [0.8; 0.8– 0.9]
Biomicroscopy recordeda 432 [6.8] 598 [8.4] 578 [6.6] 485 [5.1] 605 [5.4] 537 [4.5] 515 [3.8] 623 [4.5] 820 [6.0] 725 [5.1] 5918 [5.4; 5.2– 5.5]
STDR 106 [1.7] 155 [2.2] 148 [1.7] 129 [1.3] 181 [1.6] 149 [1.2] 179 [1.3] 210 [1.5] 211 [1.6] 246 [1.7] 1714 [1.6; 1.5– 1.6]
STR 29 [0.5] 55 [0.8] 47 [0.5] 42 [0.4] 55 [0.5] 44 [0.4] 55 [0.4] 75 [0.5] 71 [0.5] 87 [0.6] 560 [0.5; 0.5– 0.6]
STM 84 [1.3] 128 [1.8] 115 [1.3] 105 [1.1] 158 [1.4] 123 [1.0] 151 [1.1] 168 [1.2] 181 [1.3] 200 [1.4] 1413 [1.3; 1.2– 1.3]
Unknown STR & Unknown STM 0 [0.0] 2 [<0.1] 1 [<0.1] 3 [<0.1] 0 [0.0] 4 [<0.1] 1 [<0.1] 1 [<0.1] 0 [0.0] 0 [0.0] 12 [<0.1; 0.0– 0.0]
Not STDR 326 [5.1] 443 [6.2] 430 [4.9] 356 [3.7] 424 [3.8] 388 [3.2] 333 [2.5] 413 [3.0] 609 [4.5] 459 [3.2] 4181 [3.8; 3.7– 3.9]
Unknown STDR status 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0] 3 [<0.1] 0 [0.0] 0 [0.0] 20 [0.1] 23 [<0.1; 0.0– 0.0]
No biomicroscopy recordeda 54 [0.9] 100 [1.4] 108 [1.2] 64 [0.7] 119 [1.1] 107 [0.9] 42 [0.3] 53 [0.4] 55 [0.4] 110 [0.8] 812 [0.7; 0.7– 0.8]
Screen negative 5863 [92.3] 6457 [90.2] 8083 [92.2] 9036 [94.3] 10524 [93.6] 11393 [94.6] 13004 [95.9] 13228 [95.1] 12722 [93.6] 13300 [94.1] 103,610 [93.9; 93.8– 94.0]
Retinopathy level
Screen negative DR
R0R0 3816 [60.1] 4390 [61.4] 5476 [62.4] 6570 [68.5] 7682 [68.3] 8432 [70.1] 791 [72.2] 10370 [74.6] 10166 [74.8]b 10850 [76.8]b 77,543 [70.3; 70.0– 70.5]
R1R0 1234 [19.4] 1327 [18.5] 1673 [19.1] 1475 [15.4] 1727 [15.4] 1838 [15.3] 1812 [13.4] 1694 [12.2] 1666 [12.3]b 1488 [10.5]b 15,934 [14.4; 14.2– 14.6]
R1R1 830 [13.1] 800 [11.2] 1000 [11.4] 1030 [10.7] 1124 [10.0] 1172 [9.7] 1433 [10.6] 1213 [8.7] 959 [7.1] 1022 [7.2] 10,583 [9.6; 9.4– 9.8]
One assessable eye (R0) 117 [1.8] 132 [1.8] 125 [1.4] 109 [1.1] 171 [1.5] 182 [1.5] 174 [1.3] 230 [1.7] 339 [2.5] 331 [2.3] 1910 [1.7; 1.7– 1.8]
One assessable eye (R1) 5 [0.6] 48 [0.7] 56 [0.6] 57 [0.6] 5 [0.5] 52 [0.4] 44 [0.3] 54 [0.4] 76 [0.6] 54 [0.4] 531 [0.5; 0.4– 0.5]
Unknown 59 [0.9] 124 [1.7] 126 [1.4] 68 [0.7] 134 [1.2] 72 [0.6] 2 [<0.1] 5 [<0.1] 4 [<0.1] 8 [0.1] 602 [0.5; 0.5– 0.6]
Screen positive DR
R2 or M1 253 [4.0] 317 [4.4] 301 [3.4] 262 [2.7] 344 [3.1] 279 [2.3] 292 [2.2] 338 [2.4] 387 [2.8] 382 [2.7] 3155 [2.9; 2.8– 3.0]
R3 5 [0.1] 17 [0.2] 12 [0.1] 14 [0.1] 11 [0.1] 10 [0.1] 13 [0.1] 0 [0.0] 0 [0.0] 0 [0.0] 82 [0.1; 0.1– 0.1]
Note: STM and STR are not mutually exclusive categories. 95% CI are based on the Wilson score method.
Abbreviation: DR, diabetic retinopathy.
aBiomicroscopy must be recorded within 1 year of screening appointment when positive screen result occurred.
bAdjusted for subjects recruited to the ISDR RCT and assigned to 24- month screening intervals.
14 of 15 |   CHEYNE Et al.
and STDR in people with type 1 diabetes. Lower rates of as-
sessable images and other eye disease in these individuals 
compared to those with type 2 diabetes are likely to reflect 
younger age. Interestingly, type of diabetes was not identified 
as being predictive for referable DR by the Liverpool Risk 
Calculation Engine.14 However, this may reflect a low num-
ber of events in the dataset used.
We have shown that in an established screening pro-
gramme with a stable population, rates of screen positive DR 
show a consistent fall over time to a low level. The annual 
incidence of STDR is under 2% highlighting the need for fu-
ture work defining screen positive and supporting extended 
intervals for people at low risk. Higher rates of disease are 
seen in new screened patients and previous non- attenders 
who should be specifically targeted, and in people with type 
1 diabetes. Our results should be generalised with caution, 
particularly in populations with higher rates of STDR, higher 
proportions of ethnic minorities and programmes in set- up. 
Our data represent a benchmark against which other screen-
ing programmes can be measured and will inform both re-
design of screening services and future intervention studies.
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